Italia Markets closed

argenx SE (ARGX)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
394,47+6,60 (+1,70%)
Alla chiusura: 04:00PM EDT
410,00 +15,53 (+3,94%)
Dopo ore: 07:45PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente387,87
Aperto391,56
Denaro394,09 x 200
Domanda395,09 x 100
Min-Max giorno387,04 - 399,49
Intervallo di 52 settimane327,73 - 550,76
Volume561.048
Media Volume254.882
Capitalizzazione23,444B
Beta (mensile su 5 anni)0,34
Rapporto PE (ttm)N/D
EPS (ttm)-5,69
Prossima data utili25 lug 2024 - 29 lug 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A478,62
  • GlobeNewswire

    argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

    VYVGARTⓇ is the first-and-only neonatal Fc receptor (FcRn) blocker authorized for sale in Canada Approval based on the positive Phase 3 ADAPT trial (p<0.0001) showing 68% of VYVGART-treated patients were responders on the MG-ADL scale compared to 30% of placebo patients after one treatment cycle Amsterdam, The Netherlands —Sep. 21, 2023—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today anno

  • GlobeNewswire

    argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis

    Positive opinion based on Phase 3 ADAPT-SC study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered efgartigimod, compared to intravenous (IV) administrationEuropean Commission (EC) decision on marketing authorization application (MAA) expected within approximately 60 days Amsterdam, The Netherlands—September 15, 2023—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimm

  • GlobeNewswire

    argenx to Present at Upcoming Investor Conferences

    August 30, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in several upcoming investor conferences in September: Citi's 18th Annual BioPharma Conference. Fireside chat on Wednesday, September 6, 2023 at 4:20 p.m. ET in Boston, MA.Wells Fargo Healthcare Conference. Fireside chat on Thursday, September 7, 2